Is CorMedix Stock a Good Investment?
CorMedix Investment Advice | CRMD |
- Examine CorMedix's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research CorMedix's leadership team and their track record. Good management can help CorMedix navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact CorMedix's business and its evolving consumer preferences.
- Compare CorMedix's performance and market position to its competitors. Analyze how CorMedix is positioned in terms of product offerings, innovation, and market share.
- Check if CorMedix pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about CorMedix's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in CorMedix stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if CorMedix is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | OK | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine CorMedix Stock
Researching CorMedix's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 40.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.8. CorMedix last dividend was issued on the 26th of March 2019. The entity had 1:5 split on the 26th of March 2019.
To determine if CorMedix is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding CorMedix's research are outlined below:
| CorMedix is way too risky over 90 days horizon | |
| CorMedix appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (46.34 M) with profit before overhead, payroll, taxes, and interest of 10.25 M. | |
| CorMedix currently holds about 64.62 M in cash with (38.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.57. | |
| CorMedix has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a ... |
CorMedix Quarterly Accounts Payable |
|
CorMedix uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in CorMedix. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to CorMedix's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact CorMedix's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises CorMedix's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-05-13 | 2021-03-31 | -0.18 | -0.2 | -0.02 | 11 | ||
2024-05-09 | 2024-03-31 | -0.28 | -0.25 | 0.03 | 10 | ||
2022-03-29 | 2021-12-31 | -0.23 | -0.2 | 0.03 | 13 | ||
2021-03-30 | 2020-12-31 | -0.22 | -0.19 | 0.03 | 13 | ||
2020-11-05 | 2020-09-30 | -0.25 | -0.22 | 0.03 | 12 | ||
2020-03-16 | 2019-12-31 | -0.24 | -0.21 | 0.03 | 12 | ||
2019-11-14 | 2019-09-30 | -0.25 | -0.22 | 0.03 | 12 | ||
2019-08-13 | 2019-06-30 | -0.21 | -0.24 | -0.03 | 14 |
CorMedix Target Price Consensus
CorMedix target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. CorMedix's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 4 | Strong Buy |
Most CorMedix analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand CorMedix stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of CorMedix, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationCorMedix Target Price Projection
CorMedix's current and average target prices are 10.97 and 16.50, respectively. The current price of CorMedix is the price at which CorMedix is currently trading. On the other hand, CorMedix's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On CorMedix Target Price
CorMedix Analyst Ratings
CorMedix's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about CorMedix stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of CorMedix's financials, market performance, and future outlook by experienced professionals. CorMedix's historical ratings below, therefore, can serve as a valuable tool for investors.Know CorMedix's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as CorMedix is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CorMedix backward and forwards among themselves. CorMedix's institutional investor refers to the entity that pools money to purchase CorMedix's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Kennedy Capital Management Inc | 2024-12-31 | 378.2 K | Palisades Investment Partners, Llc | 2024-12-31 | 364 K | Group One Trading, Lp | 2024-12-31 | 312.1 K | Citadel Advisors Llc | 2024-12-31 | 293.6 K | Jpmorgan Chase & Co | 2024-12-31 | 273.2 K | Simplex Trading, Llc | 2024-12-31 | 210.4 K | Goldman Sachs Group Inc | 2024-12-31 | 198.9 K | Wellington Management Company Llp | 2024-12-31 | 178.8 K | Millennium Management Llc | 2024-12-31 | 178.1 K | Blackrock Inc | 2024-12-31 | 4.6 M | Vanguard Group Inc | 2024-12-31 | 3.4 M |
CorMedix's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 632.86 M.Market Cap |
|
CorMedix's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.51) | (0.53) | |
| Return On Capital Employed | (0.80) | (0.84) | |
| Return On Assets | (0.51) | (0.53) | |
| Return On Equity | (0.76) | (0.72) |
Determining CorMedix's profitability involves analyzing its financial statements and using various financial metrics to determine if CorMedix is a good buy. For example, gross profit margin measures CorMedix's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of CorMedix's profitability and make more informed investment decisions.
Please note, the presentation of CorMedix's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CorMedix's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of CorMedix's management manipulating its earnings.
Evaluate CorMedix's management efficiency
CorMedix has return on total asset (ROA) of (0.3769) % which means that it has lost $0.3769 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6504) %, meaning that it created substantial loss on money invested by shareholders. CorMedix's management efficiency ratios could be used to measure how well CorMedix manages its routine affairs as well as how well it operates its assets and liabilities. As of March 20, 2025, Return On Tangible Assets is expected to decline to -0.53. In addition to that, Return On Capital Employed is expected to decline to -0.84. At present, CorMedix's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 3.2 M, whereas Return On Tangible Assets are forecasted to decline to (0.53).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.24 | 1.30 | |
| Tangible Book Value Per Share | 1.24 | 1.30 | |
| Enterprise Value Over EBITDA | (3.49) | (3.67) | |
| Price Book Value Ratio | 2.46 | 2.58 | |
| Enterprise Value Multiple | (3.49) | (3.67) | |
| Price Fair Value | 2.46 | 2.58 | |
| Enterprise Value | 133.6 M | 140.3 M |
CorMedix has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Beta 1.529 |
Basic technical analysis of CorMedix Stock
As of the 20th of March, CorMedix shows the Mean Deviation of 3.5, downside deviation of 3.93, and Risk Adjusted Performance of 0.0615. CorMedix technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm CorMedix value at risk, and the relationship between the jensen alpha and semi variance to decide if CorMedix is priced correctly, providing market reflects its regular price of 10.97 per share. Given that CorMedix has jensen alpha of 0.4413, we suggest you to validate CorMedix's prevailing market performance to make sure the company can sustain itself at a future point.CorMedix's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CorMedix insiders, such as employees or executives, is commonly permitted as long as it does not rely on CorMedix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CorMedix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
CorMedix's Outstanding Corporate Bonds
CorMedix issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. CorMedix uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CorMedix bonds can be classified according to their maturity, which is the date when CorMedix has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand CorMedix's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing CorMedix's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0615 | |||
| Market Risk Adjusted Performance | 0.2613 | |||
| Mean Deviation | 3.5 | |||
| Semi Deviation | 3.61 | |||
| Downside Deviation | 3.93 | |||
| Coefficient Of Variation | 1658.43 | |||
| Standard Deviation | 5.45 | |||
| Variance | 29.67 | |||
| Information Ratio | 0.0763 | |||
| Jensen Alpha | 0.4413 | |||
| Total Risk Alpha | 0.9182 | |||
| Sortino Ratio | 0.1058 | |||
| Treynor Ratio | 0.2513 | |||
| Maximum Drawdown | 37.32 | |||
| Value At Risk | (6.38) | |||
| Potential Upside | 7.48 | |||
| Downside Variance | 15.42 | |||
| Semi Variance | 13.0 | |||
| Expected Short fall | (4.30) | |||
| Skewness | 2.59 | |||
| Kurtosis | 12.63 |
| Risk Adjusted Performance | 0.0615 | |||
| Market Risk Adjusted Performance | 0.2613 | |||
| Mean Deviation | 3.5 | |||
| Semi Deviation | 3.61 | |||
| Downside Deviation | 3.93 | |||
| Coefficient Of Variation | 1658.43 | |||
| Standard Deviation | 5.45 | |||
| Variance | 29.67 | |||
| Information Ratio | 0.0763 | |||
| Jensen Alpha | 0.4413 | |||
| Total Risk Alpha | 0.9182 | |||
| Sortino Ratio | 0.1058 | |||
| Treynor Ratio | 0.2513 | |||
| Maximum Drawdown | 37.32 | |||
| Value At Risk | (6.38) | |||
| Potential Upside | 7.48 | |||
| Downside Variance | 15.42 | |||
| Semi Variance | 13.0 | |||
| Expected Short fall | (4.30) | |||
| Skewness | 2.59 | |||
| Kurtosis | 12.63 |
Consider CorMedix's intraday indicators
CorMedix intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of CorMedix stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
CorMedix Corporate Filings
| 5th of February 2025 Other Reports | ViewVerify | |
F4 | 22nd of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 7th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 18th of December 2024 Other Reports | ViewVerify |
CorMedix Stock media impact
Far too much social signal, news, headlines, and media speculation about CorMedix that are available to investors today. That information is available publicly through CorMedix media outlets and privately through word of mouth or via CorMedix internal channels. However, regardless of the origin, that massive amount of CorMedix data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of CorMedix news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of CorMedix relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to CorMedix's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive CorMedix alpha.
CorMedix Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards CorMedix can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
CorMedix Maximum Pain Price Across June 20th 2025 Option Contracts
CorMedix's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of CorMedix close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of CorMedix's options.
CorMedix Corporate Management
| Kaufman Esq | Chief EVP | Profile | |
| Joseph MBA | CEO Director | Profile | |
| Donna Ucci | Senior Quality | Profile | |
| Tushar Mukherjee | Senior Operations | Profile | |
| Phoebe Esq | Gen EVP | Profile | |
| Elizabeth BA | Executive Affairs | Profile | |
| Erin Mistry | Executive Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CorMedix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CorMedix. If investors know CorMedix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CorMedix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.80) | Revenue Per Share | Quarterly Revenue Growth (0.47) | Return On Assets | Return On Equity |
The market value of CorMedix is measured differently than its book value, which is the value of CorMedix that is recorded on the company's balance sheet. Investors also form their own opinion of CorMedix's value that differs from its market value or its book value, called intrinsic value, which is CorMedix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CorMedix's market value can be influenced by many factors that don't directly affect CorMedix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between CorMedix's value and its price, as these two are different measures arrived at by various means. Investors typically determine if CorMedix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CorMedix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.